OptimalM-Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population
- 1 June 2018
- journal article
- research article
- Published by Institute for Operations Research and the Management Sciences (INFORMS) in Operations Research
- Vol. 66 (3) , 673-696
Abstract
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the fastest-growing cause of cancer-related deaths in the United States. Most HCC cases are attributed to chronic hepatitis C virus infection, which affects nearly 3 million Americans and 100 million people globally. Although surveillance for HCC in hepatitis C patients can improve survival, the optimal surveillance policies remain unknown. In this study, we develop a mixed-integer programming (MIP)-based framework to systematically analyze a rich set of policies and determine the optimal HCC surveillance policies that maximize societal net benefit. Our MIP-based framework addresses two problem features that make dynamic programming-based formulation computationally intractable. In particular, our proposed framework allows the formulation of (1) M-switch policies that are practical for implementation and (2) tailored surveillance policies with screening intervals stratified by the precursor disease states. We theoretically analyze the HCC surveillance problem, characterize when the surveillance policies should be adapted to populations with different disease progression rates, and quantify the trade-off between decreasing HCC incidence and increasing treatment outcomes. We parameterize our model using clinical trial data, a previously validated simulation model, and published clinical studies. Our numerical analyses lead to three main results with important policy implications. First, we find that, in addition to cirrhotic patients, expanding surveillance to patients in the earlier stages of hepatitis C infection improves the cost-effectiveness of HCC surveillance. Second, compared with the “one size fits all” routine policies, we find that it is cost-effective to stratify surveillance strategies based on the stage of hepatitis C infection with less frequent cancer surveillance in the earlier stages of infection. Finally, we find that a little flexibility in the policy structure as captured by M-switch policies is sufficient to capture almost as much benefit as from complex fully dynamic policies.The e-companion is available at https://doi.org/10.1287/opre.2017.1706 .Keywords
This publication has 84 references indexed in Scilit:
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis CHepatology, 2011
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed?Hepatology, 2010
- Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic FactorsOperations Research, 2010
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005Journal of Clinical Oncology, 2009
- Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysisBritish Journal of Cancer, 2008
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- An Algorithm for the Grading of Activity in Chronic Hepatitis CHepatology, 1996